93 related articles for article (PubMed ID: 10414179)
1. Molecular aspects of hepatocellular carcinoma.
Abou-Shady M; Baer HU; Friess H; Zimmermann A; Büchler MW
Swiss Surg; 1999; 5(3):102-6. PubMed ID: 10414179
[TBL] [Abstract][Full Text] [Related]
2. Fibulin-5 inhibits hepatocellular carcinoma cell migration and invasion by down-regulating matrix metalloproteinase-7 expression.
Tu K; Dou C; Zheng X; Li C; Yang W; Yao Y; Liu Q
BMC Cancer; 2014 Dec; 14():938. PubMed ID: 25494879
[TBL] [Abstract][Full Text] [Related]
3. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.
Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B
J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718
[TBL] [Abstract][Full Text] [Related]
4. RAB10 overexpression promotes tumor growth and indicates poor prognosis of hepatocellular carcinoma.
Wang W; Jia WD; Hu B; Pan YY
Oncotarget; 2017 Apr; 8(16):26434-26447. PubMed ID: 28460436
[TBL] [Abstract][Full Text] [Related]
5. Decreased expression of PBLD correlates with poor prognosis and functions as a tumor suppressor in human hepatocellular carcinoma.
Li A; Yan Q; Zhao X; Zhong J; Yang H; Feng Z; Du Y; Wang Y; Wang Z; Wang H; Zhou Y; Liu S; Nie Y
Oncotarget; 2016 Jan; 7(1):524-37. PubMed ID: 26594798
[TBL] [Abstract][Full Text] [Related]
6. Tissue biomarkers of prognostic significance in hepatocellular carcinoma.
Pinato DJ; Pirisi M; Maslen L; Sharma R
Adv Anat Pathol; 2014 Jul; 21(4):270-84. PubMed ID: 24911252
[TBL] [Abstract][Full Text] [Related]
7. Cancer-related microRNAs and their role as tumor suppressors and oncogenes in hepatocellular carcinoma.
Gailhouste L; Ochiya T
Histol Histopathol; 2013 Apr; 28(4):437-51. PubMed ID: 23224781
[TBL] [Abstract][Full Text] [Related]
8. Over-expression of Thrombospondin 4 correlates with loss of miR-142 and contributes to migration and vascular invasion of advanced hepatocellular carcinoma.
Su F; Zhao J; Qin S; Wang R; Li Y; Wang Q; Tan Y; Jin H; Zhu F; Ou Y; Cheng Z; Su W; Zhao F; Yang Y; Zhou Z; Zheng J; Li Y; Li Z; Wu Q
Oncotarget; 2017 Apr; 8(14):23277-23288. PubMed ID: 28177895
[TBL] [Abstract][Full Text] [Related]
9. Decreased Expression of Fructose-1,6-bisphosphatase Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma.
Hirata H; Sugimachi K; Komatsu H; Ueda M; Masuda T; Uchi R; Sakimura S; Nambara S; Saito T; Shinden Y; Iguchi T; Eguchi H; Ito S; Terashima K; Sakamoto K; Hirakawa M; Honda H; Mimori K
Cancer Res; 2016 Jun; 76(11):3265-76. PubMed ID: 27197151
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of castor zinc finger 1 predicts poor prognosis and facilitates hepatocellular carcinoma progression via MAPK/ERK signaling.
Wang JL; Yang MY; Xiao S; Sun B; Li YM; Yang LY
J Exp Clin Cancer Res; 2018 Mar; 37(1):45. PubMed ID: 29506567
[TBL] [Abstract][Full Text] [Related]
11. Characterization of genome-wide TFCP2 targets in hepatocellular carcinoma: implication of targets FN1 and TJP1 in metastasis.
Xu X; Liu Z; Zhou L; Xie H; Cheng J; Ling Q; Wang J; Guo H; Wei X; Zheng S
J Exp Clin Cancer Res; 2015 Jan; 34(1):6. PubMed ID: 25609232
[TBL] [Abstract][Full Text] [Related]
12. POU2F1 over-expression correlates with poor prognoses and promotes cell growth and epithelial-to-mesenchymal transition in hepatocellular carcinoma.
Zhong Y; Huang H; Chen M; Huang J; Wu Q; Yan GR; Chen D
Oncotarget; 2017 Jul; 8(27):44082-44095. PubMed ID: 28489585
[TBL] [Abstract][Full Text] [Related]
13. BPTF promotes hepatocellular carcinoma growth by modulating hTERT signaling and cancer stem cell traits.
Zhao X; Zheng F; Li Y; Hao J; Tang Z; Tian C; Yang Q; Zhu T; Diao C; Zhang C; Chen M; Hu S; Guo P; Zhang L; Liao Y; Yu W; Chen M; Zou L; Guo W; Deng W
Redox Biol; 2019 Jan; 20():427-441. PubMed ID: 30419422
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-98 acts as a tumor suppressor in hepatocellular carcinoma via targeting SALL4.
Zhou W; Zou B; Liu L; Cui K; Gao J; Yuan S; Cong N
Oncotarget; 2016 Nov; 7(45):74059-74073. PubMed ID: 27677076
[TBL] [Abstract][Full Text] [Related]
15. Reveal the molecular signatures of hepatocellular carcinoma with different sizes by iTRAQ based quantitative proteomics.
Wang Y; Liu H; Liang D; Huang Y; Zeng Y; Xing X; Xia J; Lin M; Han X; Liao N; Liu X; Liu J
J Proteomics; 2017 Jan; 150():230-241. PubMed ID: 27693406
[TBL] [Abstract][Full Text] [Related]
16. [Hepatocellular carcinoma: novel molecular aspects for differential diagnosis and therapy].
Kern MA; Schirmacher P
Verh Dtsch Ges Pathol; 2006; 90():85-98. PubMed ID: 17867584
[TBL] [Abstract][Full Text] [Related]
17. Uridine-cytidine kinase 2 upregulation predicts poor prognosis of hepatocellular carcinoma and is associated with cancer aggressiveness.
Huang S; Li J; Tam NL; Sun C; Hou Y; Hughes B; Wang Z; Zhou Q; He X; Wu L
Mol Carcinog; 2019 Apr; 58(4):603-615. PubMed ID: 30556610
[TBL] [Abstract][Full Text] [Related]
18. Small hepatocellular carcinoma: its relationship to multistep hepatocarcinogenesis.
Uchida T
Pathol Int; 1995 Mar; 45(3):175-84. PubMed ID: 7787987
[TBL] [Abstract][Full Text] [Related]
19. Hypermethylated KCNQ1 acts as a tumor suppressor in hepatocellular carcinoma.
Fan H; Zhang M; Liu W
Biochem Biophys Res Commun; 2018 Sep; 503(4):3100-3107. PubMed ID: 30144972
[TBL] [Abstract][Full Text] [Related]
20. SYNJ2BP inhibits tumor growth and metastasis by activating DLL4 pathway in hepatocellular carcinoma.
Liu X; Zhou J; Zhou N; Zhu J; Feng Y; Miao X
J Exp Clin Cancer Res; 2016 Jul; 35(1):115. PubMed ID: 27440153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
